Table 2. Individual Participant Characteristics and Ketamine Response.
| Age/Sex/Race | Age of SAD onset (years) | Current neuropsychotropic medications | Infusion order (first infusion) | Ketamine responder on LSAS and/or VAS | LSAS pre/post ketamine | VAS pre/post ketamine | HDRS17 pre/post ketamine | Max CADSS ketamine/placebo |
|---|---|---|---|---|---|---|---|---|
| 25/F/C | 14 | NONE | P | VAS | 85/86 | 30/30 | 21/7 | 3/0 |
| 25/M/A | 12 | Paroxetine | P | VAS | 99/93 | 10/0 | 18/12 | 3/2 |
| 25/M/C | 4 | NONE | K | Non-responder | 94/94 | 35/20 | 26/22 | 0/0 |
| 30/M/C | 6 | Alprazolam, gabapentin | K | VAS | 84/92 | 25/25 | 13/8 | 9/0 |
| 22/M/C | 13 | Risperidone, sertraline, bupropion | K | LSAS+VAS | 126/45 | 60/0 | 20/2 | 9/0 |
| 30/F/C | 18 | Paroxetine | P | VAS | 70/71 | 65/0 | 5/0 | 22/0 |
| 32/M/A | 13 | Bupropion | P | VAS | 96/96 | 90/65 | 28/24 | 5/3 |
| 24/F/C | 13 | NONE | P | LSAS | 52/53 | 55/55 | 22/14 | 16/10 |
| 18/M/C | 11 | Lisdexamfetamine, sertraline, amitriptyline | P | VAS | 91/76 | 30/15 | 21/10 | 8/0 |
| 44/F/C | 5 | Amphetamine/ dextroamphetamine mixed salts, clonazepam | K | LSAS+VAS | 89/59 | 65/5 | 25/9 | 0/0 |
| 33/M/C | 30 | NONE | P | VAS | 129/128 | 50/50 | 25/9 | 2/9 |
| 61/M/C | Unknown | NONE | K | LSAS+VAS | 72/34 | 60/30 | 1/3 | 6/0 |
| 29/M/C | 17 | Escitalopram | K | VAS | 85/67 | 75/20 | 21/20 | 17/0 |
| 48/F/C | 12 | NONE | P | VAS | 81/67 | 50/10 | 16/5 | 9/0 |
| 24/M/C | 14 | NONE | K | LSAS+VAS | 79/75 | 25/10 | 11/5 | 8/0 |
| 23/F/C | 19 | NONE | P | VAS | 84/85 | 35/60 | 5/3 | 12/6 |
| 18/M/C | 13 | NONE | K | LSAS+VAS | 112/63 | 50/20 | 6/6 | 27/0 |
| 24/F/C | 5 | NONE | K | VAS | 94/66 | 30/10 | 12/0 | 5/— |
Abbreviations: A, Asian; C, Caucasian; CADSS, Clinician Administered Dissociative States Scale; F, Female; HDRS17, 17-item Hamilton Depression Rating Scale; K, Ketamine; LSAS, Leibowitz Social Anxiety Scale; M, Male; P, Placebo; SAD, social anxiety disorder; VAS, Visual Analog Scale for Anxiety.
This table displays the individual characteristics for the participants in the trial listed in order of trial enrollment. Pre/post ketamine and saline results are indicative of scores received on Day 0 prior to the infusion and on Day 1 (24 h after the infusion), respectively. Response could occur at any point during the 14 days following infusion (ie some patients responded after Day 1).